-- Catalent Seeks $400 Million Loan for Aptuit Unit Purchase
-- B y   M i c h a e l   A m a t o
-- 2012-02-13T21:39:24Z
-- http://www.bloomberg.com/news/2012-02-13/catalent-seeks-400-million-loan-for-aptuit-unit-purchase-1-.html
Catalent Pharma Solutions Inc., the
provider of development services to the pharmaceutical industry,
is seeking a $400 million term loan to back its acquisition of
Aptuit LLC’s clinical-trial supplies business, according to a
person with knowledge of the transaction.  Morgan Stanley is arranging the financing for the Somerset,
New Jersey-based company and will hold a lender call at 10:30
a.m. tomorrow in  New York , said the person, who asked not to be
identified because details haven’t been publicized.  Catalent is also seeking to extend the maturity on its
existing U.S. dollar- and euro-denominated term loans, the
person said. As of Dec. 31, the company had $1.012 billion
outstanding on the dollar-denominated portion and 253 million
euros ($334 million) outstanding on the euro-denominated piece,
according to data compiled by Bloomberg.  Both term loans are due in April 2014 and pay 2.25
percentage points more than the London interbank offered rate
and Euribor respectively, the data shows.  The company agreed to acquire the clinical-trial supplies
business of Aptuit for $410 million in cash, according to an
Aug. 22 company statement.  Catalent was created in April 2007 when Blackstone Group
acquired the pharmaceutical technologies and services segment of
Cardinal Health Inc. for $3.3 billion in cash, according to data
compiled by Bloomberg.  A spokesperson for Catalent wasn’t available to comment.  In a revolving credit facility, money can be borrowed again
once it’s repaid; in a term loan, it can’t. A term loan B is  To contact the editor responsible for this story:
Dennis Fitzgerald at 
 dfitzgerald5@bloomberg.net  